Study: Ariosa's Down syndrome Dx works well in broader population

Ariosa Diagnostics is getting a boost from a new study that says its Harmony Prenatal molecular diagnostics test is effective in a general screening population, and not just in high-risk patients. The test screens pregnant women for trisomies (the presence of three chromosomes instead of two), which can cause Down syndrome and other genetic conditions. Researchers evaluated 2,049 pregnant women for the blinded study, and all were undergoing routine screening for fetal trisomy in the first trimester. Typically, tests for fetal trisomy are conducted in high-risk patients (women older than age 35), rather than in the general population. Release

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.